

Lower extremity lymphedema after pelvic nodal dissection for urologic cancers is associated with metastatic recurrence

Kaylyn Pogson¹, Gianpaolo P. Carpinito², Fernando Mijares-Diaz¹, Sabrina A Mangat¹, Kamran Khan¹, Marc A. Bjurlin², Adeyemi Ogunleye^{1,2}

¹Division of Plastic Surgery, University of North Carolina, Chapel Hill, NC, United States; ²Division of Plastic Surgery, University of North Carolina, Chapel Hill, NC, United States

Cite as: Pogson K, Carpinito GP, Mijares-Diaz F, et al. Lower extremity lymphedema after pelvic nodal dissection for urologic cancers is associated with metastatic recurrence. *Can Urol Assoc J* 2025;19(11):E386-91. <http://dx.doi.org/10.5489/cuaj.9193>

Published online July 28, 2025

ABSTRACT

INTRODUCTION: We aimed to evaluate the incidence and risk factors for lymphedema secondary to pelvic lymph node dissection (PLND) in urologic surgery. Secondary lymphedema is the most common type of lymphedema in the U.S. and the role of PLND in lower extremity lymphedema etiology is less well-defined.

METHODS: We performed a retrospective review of all PLNDs performed for urologic malignancies at a single academic institution between April 2014 and April 2017. Patient demographics, comorbidities, cancer staging, and other treatment information were collected. Incidence of lower extremity lymphedema and associated risk factors were explored. Univariate analysis and multivariate logistic regression were performed.

RESULTS: A total of 235 patients were included in our study. Mean (standard deviation) age was 68.8 (8.9) years, and the mean followup duration was 2.4 (1.7) years. Lymphedema occurred in 22 (9.4%) patients, and the mean time to lymphedema diagnosis was 7.4 (8.0) months. Age, body mass index, smoking, diabetes, pre- or postoperative radiation, number of resected lymph nodes, and number of positive lymph nodes were not significantly associated with postoperative lower extremity lymphedema; however, metastatic recurrence was significantly associated with the development of postoperative lymphedema. (odds ratio 2.83, 95% confidence interval 1.1–7.32, $p=0.03$).

CONCLUSIONS: While the incidence of lower extremity lymphedema after PLND is low in urologic cancer patients, this complication is associated with metastatic recurrence. These results may allow for improved preoperative counseling on the risk of lower extremity lymphedema and inform cancer surveillance in patients with this complication. More research is needed to elucidate this association.

INTRODUCTION

Secondary lymphedema due to iatrogenic or other injury is the most common type of lymphedema in the developed world.¹ Up to one in 1000 people in the U.S. and as many as one in six cancer survivors suffer from this chronic progressive condition.² Cancer-related lymphedema is postulated to occur due to fibrosis and loss of capillary lymphatics following regional lymphadenectomy, with adjuvant therapies such as radiation likely contributing as well.^{3,4}

Axillary and inguinal lymph node dissection for breast and other cancers are well-described risk factors for lymphedema of the upper and lower limb, respectively; however, comparatively little is known about the relationship of regional lymphadenectomy and cancer-related lymphedema in other settings.

Specifically, substantially less is known about the role of pelvic lymph node dissection (PLND) in the etiology of lower extremity lymphedema (LEL) despite frequent occurrence and significant impact on patients. PLND is the gold standard for the detection and staging of nodal metastases in the evaluation of urogynecologic cancers.⁵ PLND accordingly represents an exceedingly common component of treatment for urologic and gynecologic malignancies and has been associated with an incidence of lymphedema of 36–47% after gynecologic cancer and up to 20% after treatment of urologic pelvic malignancies.^{6–8}

LEL represents a not uncommon and relevant yet poorly understood sequela of PLND. Importantly, the comprehensive burden of LEL sur-

passes that of the upper extremity, with more frequent hospitalizations and higher costs of hospitalization.⁹ Less readily quantifiable, lymphedema of the extremities has been shown more generally to pose significant deleterious effects to patients' quality of life.¹⁰

Though PLND remains prognostically useful, optimal patient selection for this intervention remains controversial due to the uncertain therapeutic benefit of PLND and a host of associated perioperative and long-term side effects, such as LEL. Therefore, significant interest is focused on identifying patients who are most likely to benefit from and least likely to suffer harms from PLND.^{11,12} With little known about risk factors for LEL in patients undergoing pelvic lymphadenectomy for urologic cancers, we sought to identify risk factors associated with this complication.

METHODS

Study design and population

Through retrospective review, we identified all patients who underwent PLND for urologic malignancies at an academic institution between April 2014 and April 2017. Cases were identified through a combination of extraction based on diagnostic and procedural codes and individual data abstraction from the chart. The final analytic sample comprised 235 patients. The only exclusion criterion considered was LEL predating cancer treatment, which resulted in no exclusions.

Variables

The primary outcome was development of LEL, which was identified on chart review. A patient was determined to have LEL based on clinical diagnosis using limb size measurement during postoperative patient encounters as recorded in documentation within the electronic health record (EHR). Routine followup included visits at 2–4 weeks, followed by visits at three, six, 12, and 24 months.

Limb size was compared to unaffected limb for unilateral lymphedema or prior size based on patient history and exam. Patients were assessed for deep venous thrombosis, and ultrasound imaging was obtained as clinically indicated. Covariates of interest, including patient demographics, comorbidities, cancer staging, index surgery operative parameters, and postoperative treatment information, were also collected through retrospective chart review.

Table 1. Demographic features of patients undergoing pelvic lymphadenectomy for urologic cancer

Characteristic	n (%)
Age (years), mean (SD)	68.8 (8.9)
Gender	
Female	42 (17.9)
BMI (kg/m ²), mean (SD)	27.2 (4.7)
Diagnosis	Diagnosis
Urothelial cancer	Urothelial cancer
Prostate cancer	Prostate cancer
Others	Others
Minimally invasive access (robotic, laparoscopic)	120 (51.1)
Open	115 (48.9)
Operative time (mins), mean (SD)	351.7 (95.1)
Number of nodes, mean (SD)	17.8 (12.1)
Number of positive nodes, mean (SD)	1.0 (3.8)
Estimated blood loss (median in ml)	300
Followup in yrs, mean (SD)	2.4 (1.7)
Time of lymphedema onset (months), mean (SD)	7.4 (8.2)
Length of hospital stay (days), mean (SD)	6.1 (5.7)
Postop lymphedema	22 (9.4)
Smoking	133 (61.6)
Diabetes	60 (25.9)
Local recurrence	32 (13.6)
Metastatic recurrence	71 (30.2)
Preop chemotherapy	103 (43.8)
Preop immunotherapy	49 (20.9)
Preop radiation	8 (3.4)
Postop chemotherapy	24 (10.2)
Postop immunotherapy	23 (9.8)
Postop radiotherapy	9 (3.8)
Mortality	61 (26)
Complications	
Any complication	201 (85.5)
Infection	19 (8.1)
UTI	15 (6.4)
Anemia	14 (6.0)
Ileus	12 (5.1)

BMI: body mass index; SD: standard deviation; UTI: urinary tract infection.

Statistical analysis

Univariate analyses with Chi-squared tests were performed for categorical variables, and t-tests were performed for continuous variables. Multivariable logistic regression was used to determine the relationships between LEL and covariates of interest. Models were created based on known associations in the literature, as well as univariate test results. Missing data were handled using indicator variables.

All analyses were performed using SAS version 9.4 M8.

RESULTS

Population characteristics

The final analytic sample consisted of 235 patients who had undergone PLND during the period of interest. Of this sample, 17.9%, were female. Mean (standard deviation [SD]) age and followup of participants were 68.8 (8.9) and 2.4 (1.7) years, respectively. Meanwhile, 61.6% endorsed tobacco use, and 25.9% had diabetes. Most individuals were diagnosed with urothelial cancer (94%), while only a minority were diagnosed with prostate (3%) and other types of urologic cancers (3%). We noted a low rate of PLND performed with prostatectomy because PLND was not routinely performed on patients with intermediate-risk disease during this time frame. The majority of low- and high-risk prostate cancer patients meanwhile, received active surveillance or radiation, respectively. Mean (SD) total and positive lymph node yields were 17.8 (12) and 1 (3.8), respectively. In total, 30.2% of patients developed metastatic recurrence of their primary malignancy (Table 1).

Lower extremity lymphedema characteristics and risk factors

Of the 235 individuals participating in the study, 22 (9.4%) were diagnosed with LEL at a mean (SD) of 7.4 months after surgery. Among these patients who developed lymphedema, mean (SD) age was 69.1 (11.1) years, and body mass index (BMI) was 28.1 (3.9). Mean (SD) total and positive lymph node yields were 21.5 (12.1) and 1.4 (3.9), respectively. Of the individuals who developed lymphedema, 22 (100%) had urothelial cancer, and eight (36.4%) had both urothelial and prostate cancer (Table 2). There were 14 patients with LEL (63% of all LEL patients) who developed metastatic recurrence: four (18%) were in the pelvis, three (13.6%) in the lungs, two (9%) in the abdomen, and one (4.5%) each in the retroperitoneum, spine, ureters or kidney, ilium, and the liver (Table 2).

Table 2. Characteristics of lower extremity lymphedema after pelvic lymphadenectomy for urologic cancer

	n (%)
Total	22 (9.4)
Diagnosis	
Urothelial cancer	22 (100)
Urothelial and prostate cancer	8 (36.4)
Time of lymphedema onset (months), mean (SD)	7.4 (8.0)
Site of metastasis	
Bone	5 (22.7)
Lung	3 (13.6)
Abdomen/liver	3 (13.6)
Site of lymphedema	
Bilateral	8 (36.4)
Unilateral left	8 (36.4)
Unilateral right	6 (27.2)

SD: standard deviation.

Risk factors for development of lower extremity lymphedema

Demographic characteristics, including age, BMI, and gender, were similar between LEL and non-LEL groups, and did not significantly differ on univariate and multivariate analyses. Mean (SD) operative time for patients who did and did not develop LEL were 358.2 (73.6) vs. 351.0 (96.8) minutes ($p=0.79$), respectively. A positive trend in the yield of total and positive nodes was observed for LEL patients, although this relationship did not reach significance.

Mean (SD) total nodal yields were 21.5 (12.2) vs. 17.4 (12.2) ($p = 0.15$) for LEL and non-LEL patients, respectively. Mean (SD) positive nodal yields were 1.4 (3.9) vs. 1.0 (3.8) ($p=0.66$) for LEL and non-LEL patients, respectively.

Rates of pN+ status were 42 (20.6%) vs. five (22.7%) ($p=0.5$) for patients with and without LEL, respectively. Overall, one (4.5%) of the LEL patients received neoadjuvant radiation compared with seven (3.2%) of the non-LEL patients ($p=0.55$). No LEL patients received adjuvant radiation, although nine (4.2%) patients in the non-LEL group did.

In terms of local recurrence, two (9%) vs. 30 (14.1%) of LEL and non-LEL patients developed this sequela ($p=0.75$), respectively. Similarly, neoadjuvant or adjuvant chemotherapy and immunotherapy were not associated with LEL incidence. We noted a significant relationship between subsequent development of metastatic recurrence and LEL. Eleven (50%) vs. 60 (28.2%) LEL and non-LEL patients, respectively,

developed metastatic recurrence, reaching significance ($p=0.049$) on univariate analysis. The same significant relationship was confirmed in multivariate analysis, with an odds ratio (OR) of 2.83 (95% confidence interval 1.1–7.32) (Tables 3, 4).

DISCUSSION

In this study, we set out to better describe demographic characteristics, clinical characteristics, and risk factors for development of LEL among urologic cancer patients undergoing PLND. Overall, 9.4% of patients developed LEL and mean (SD) time to diagnosis was 7.4 (8.0) months, suggesting that the condition is common but presents with delayed onset. Significantly, all patients who developed lymphedema had urothelial cancer, and our results reflect that patients who developed LEL more frequently developed subsequent metastases. Lymph node yields were also higher (although not significantly so) among patients who developed lymphedema, potentially suggesting that the extent of lymphadenectomy may increase the risk of LEL.

To our knowledge, no other study has reported on the time to diagnosis of LEL following PLND, adding new insight to the literature. Our observed rate of lymphedema is roughly comparable to that reported by most previous studies in this space. Cormier et al, for example, found that among 1060 patients with genitourinary cancer, 11% developed lymphedema.¹³ Likewise, a more recent systematic review by Clinckaert et al found a lymphedema incidence of up to 14% after radical prostatectomy with PLND.¹⁴

Important for patients with genitourinary malignancy who sometimes receive adjuvant radiation, pelvic irradiation coupled with PLND appears to compound the risk of lower extremity lymphedema (18–29%), which should prompt physicians to revise risk estimates for such patients.¹⁴ We highlight that while common, lymphedema following PLND is, on average, diagnosed with relative delay. While this may be due to delayed onset, delayed recognition by providers, subsequent treatments, or a combination thereof, this finding underscores the need for heightened surveillance by urologic providers within the first year following surgery, especially given the potential for significant adverse impact on patients' quality of life. Ensuring adequate provider education about the timing and prevalence of LEL would significantly benefit patients.

We also noted some correlation between cancer type, risk of metastasis, and development of lymphedema. Although our sample did mostly comprise urothelial cancer patients, all patients who developed

Table 3. Risk factors for lower extremity lymphedema after pelvic lymphadenectomy for urologic cancer

Demographic factor	n (%), mean (SD)	p
Age (years)	69.1 (11.1)	0.90
BMI (kg/m ²)	28.1 (3.9)	0.47
Operative time (mins)	358.2 (73.6)	0.79
Number of nodes	21.5 (12.1)	0.15
Number of positive nodes	1.4 (3.9)	0.66
Smoking	12 (54.5)	0.80
Female gender	3 (13.6)	0.77
Neoadjuvant chemotherapy	12 (54.5)	1.0
Adjuvant chemotherapy	19 (86.3)	0.48
Neoadjuvant immunotherapy	17 (77.2)	0.79
Adjuvant immunotherapy	22 (90.9)	1.0
Neoadjuvant radiation	1 (4.5)	0.55
Adjuvant radiation	0 (0)	n/a
Local recurrence	2 (9)	0.75
Metastatic recurrence	11 (50)	0.049
Mortality	8 (36.4)	0.32

BMI: body mass index; SD: standard deviation.

Table 4. Multivariate analysis of factors associated with postoperative lower extremity lymphedema after pelvic lymphadenectomy for urologic cancers

Variable	OR	95% CI
Metastatic recurrence	2.83	1.1–7.32
Age	1.03	0.97–1.1
Gender	0.40	0.09–1.88
BMI	1.07	0.96–1.18

BMI: body mass index; CI: confidence interval; OR: odds ratio.

lymphedema did notably have urothelial cancer. This is mirrored by prior mixed pathology studies showing a predominance of bladder cancer among lymphedema patients.¹³ Somewhat surprisingly, development of lymphedema was significantly associated with development of metastatic disease, involving 50% of patients with lymphedema in our study. Although we are not able to conclude the cause for this association based on our results, a meta-analysis by Hu et al showed 40% increased odds of LEL in cervical cancer patients with

positive lymph nodes (OR 1.40 [0.86, 2.26]), suggesting that lymphatic spread may directly or indirectly contribute to lymphatic congestion.¹⁵

Prior urologic literature notes that lymph node metastases are significantly more common in bladder cancer, occurring in roughly one-quarter of cystectomy patients, and positive lymph node status is an indicator of poor prognosis and subsequently metastatic recurrence.¹⁶ One may speculate that the presence of lymphatic metastases may lead to local changes altering lymphatic drainage. Our study did not demonstrate a relationship between pathologic nodal status and development of lymphedema; however, it is possible that nodes in our sample were pathologically understaged due to limitations in the detection of micrometastatic disease.¹⁷ Alternatively, it may also be that patients considered to have a higher risk of recurrence, as determined by the surgeon, undergo more extensive surgery, which may in turn raise the risk of lymphedema due to greater lymphatic disruption.

Lymph node yields appeared higher in patients who subsequently developed lymphedema. Whereas 17.8 nodes per patient, on average, were harvested in the cohort as a whole, 21.5 nodes per patient, on average, were harvested in the subset developing lymphedema. A prior study by Keegan et al found that extended node dissections led to higher rates of lymphedema, specifically when combined with irradiation.¹² A similar study in the endometrial cancer space by Lee et al showed increased incidence of LEL with increasing nodal yields.¹⁸ Taken together, it is likely that extended dissection results in both increased nodal yields and higher risk of clinically significant disruption of LEL drainage. These results could help inform clinical and surgical decision-making in the management of patients with urologic cancers, especially as it pertains to situations in which patients undergo extended node dissection and irradiation.

Limitations

Our study is not without limitations. We note that the retrospective nature of the study limits the quality of ascertained data. Some documentation may have been incomplete, obscuring some cases of lymphedema or relevant clinical factors in select cases. Our smaller sample size and location at a single academic institution may introduce selection bias for more complex cases, limiting generalizability of findings.

Additionally, outside of a randomized trial setting, decisions to perform PLND depend on surgeon preferences and patient selection. It is entirely possible that

performance and extent of LND may have depended on surgeon estimation of specific-patient characteristics, which could have introduced confounding into our results. Analogously, we know that PLNDs were not routinely performed with prostatectomy at our institution during our study period, limiting the generalizability of our results to prostatectomy patients. Intermediate-risk prostate cancer patients did not routinely undergo PLND, and low- and high-risk patients largely underwent active surveillance and radiation, respectively.

Future efforts will need to specifically include a diverse sample of prostatectomy patients to account for potential differences in the incidence of lymphedema based on differing patient- and disease-specific characteristics. We also note that lymphedema is, generally speaking, a clinical diagnosis, a definition we relied upon in this study. Although standard, clinical diagnosis has been augmented in previous studies by different measures, such as self-reported lymphedema, survey instruments, and differing diagnostic criteria. Differing methodologies would limit comparison between our study and others, although this is essentially unavoidable, as it reflects the state of research in this burgeoning space.

CONCLUSIONS

Improving our understanding of the incidence of LEL and associated risk factors is essential to develop sound preoperative counseling of patients with regard to the risk of lower extremity lymphedema. Our study provides important information about incidence, timing, and risk factors for this condition. At this time, the field requires further exploration of the epidemiology of LEL in urologic cancer patients and the interplay between associated risk factors and their role in the development of lymphedema.

COMPETING INTERESTS: Dr. Ogunleye received support from the UNC Lineberger Breast Cancer Specialized Program for Research Excellence. The remaining authors do not report any competing personal or financial interests related to this work.

REFERENCES

1. Rockson SG, Rivera KK. Estimating the population burden of lymphedema. *Ann N Y Acad Sci* 2008;1131:147-54. <https://doi.org/10.1196/annals.1413.014>
2. Greene A, ed. *Lymphedema: Presentation, diagnosis, and treatment*. Springer; 2015. <https://doi.org/10.1007/978-3-319-14493-1>
3. Suami H, Pan WR, Taylor GI. Changes in the lymph structure of the upper limb after axillary dissection: Radiographic and anatomical study in a human cadaver. *Plast Reconstr Surg* 2007;120:982-91. <https://doi.org/10.1097/01.prs.0000277995.25009.3e>
4. Avraham T, Yan A, Zampell JC, et al. Radiation therapy causes loss of dermal lymphatic vessels and interferes with lymphatic function by TGF- β 1-mediated tissue fibrosis. *Am J Physiol Cell Physiol* 2010;299:C589-605. <https://doi.org/10.1152/ajpcell.00535.2009>
5. Briganti A, Blute ML, Eastham JH, et al. Pelvic lymph node dissection in prostate cancer. *Eur Urol* 2009;55:1251-65. <https://doi.org/10.1016/j.eururo.2009.03.012>

6. Biglia N, Librino A, Ottino MC, et al. Lower limb lymphedema and neurological complications after lymphadenectomy for gynecological cancer. *Int J Gynecol Cancer* 2015;25:521-5. <https://doi.org/10.1097/IGC.0000000000000341>
7. Kavoussi LR, Sosa E, Chandhoke P, et al. Complications of laparoscopic pelvic lymph node dissection. *J Urol* 1993;149:322-5. [https://doi.org/10.1016/S0022-5347\(17\)36069-X](https://doi.org/10.1016/S0022-5347(17)36069-X)
8. Bianchi LMG, Irmici G, Cè M, et al. Diagnosis and treatment of post-prostatectomy lymphedema: what's new? *Curr Oncol* 2023;30:4512-26. <https://doi.org/10.3390/curroncol30050341>
9. Ogunleye AA, Nguyen DH, Lee GK. Surgical treatment of lymphedema. *JAMA Surg* 2020;155:522. <https://doi.org/10.1001/jamasurg.2020.0015>
10. Bott T. Lymphoedema and cancer: an overview. *Br J Nurs* 2022;31:120-2. <https://doi.org/10.12968/bjon.2022.31.3.120>
11. Fossati N, Willemsè PPM, Van den Broeck T, et al. The benefits and harms of different extents of lymph node dissection during radical prostatectomy for prostate cancer: a systematic review. *Eur Urol* 2017;72:84-109. <https://doi.org/10.1016/j.eururo.2016.12.003>
12. Keegan KA, Cookson MS. Complications of pelvic lymph node dissection for prostate cancer. *Curr Urol Rep* 2011;12:203-8. <https://doi.org/10.1007/s11934-011-0179-z>
13. Cormier JN, Askew RL, Mungovan KS, et al. Lymphedema beyond breast cancer. *Cancer* 2010;116:5138-49. <https://doi.org/10.1002/cncr.25458>
14. Clinckaert A, Callens K, Cooreman A, et al. The prevalence of lower limb and genital lymphedema after prostate cancer treatment: a systematic review. *Cancers (Basel)* 2022;14:5667. <https://doi.org/10.3390/cancers14225667>
15. Hu H, Fu M, Huang X, et al. Risk factors for lower extremity lymphedema after cervical cancer treatment: a systematic review and meta-analysis. *Transl Cancer Res* 2022;11:1713-21. <https://doi.org/10.21037/tcr-22-1256>
16. Svatek RS, Shariat SF, Novara G, et al. Discrepancy between clinical and pathological stage: external validation of the impact on prognosis in an international radical cystectomy cohort. *BJU Int* 2011;107:898-904. <https://doi.org/10.1111/j.1464-410X.2010.09628.x>
17. Liedberg F, Chebil G, Davidsson T, et al. Intraoperative sentinel node detection improves nodal staging in invasive bladder cancer. *J Urol* 2006;175:84-8. [https://doi.org/10.1016/S0022-5347\(05\)00066-2](https://doi.org/10.1016/S0022-5347(05)00066-2)
18. Lee J, Byun HK, Im SH, et al. Risk factors for lower extremity lymphedema after surgery in cervical and endometrial cancer. *J Gynecol Oncol* 2023;34:e28. <https://doi.org/10.3802/jgo.2023.34.e28>

CORRESPONDENCE: Dr. Adeyemi Ogunleye, Division of Plastic Surgery, University of North Carolina, Chapel Hill, NC, United States; yemi@med.unc.edu